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Abstract 
Objectives: Pituitary adenoma represents 
the most frequent tumour encountered in 
the sellar region. We have proposed to 
review the principles of diagnosis and 
treatments and to analyze their standard 
protocol of approaching pituitary lesions. 
Material and method: We have 
retrospectively analyzed the cases of 
pituitary adenoma between Jan 2006 and 
Dec 2010, we studied presenting 
symptoms, hormonal status, local 
extension, surgical approach, tumor 
histology, type of resection, tumor volume, 
cavernous sinus invasion, surgical corridors, 
recurrence rate, intra operative and 
postoperative complications 
Results: 72 patients were included in the 
study, with no significant difference 
between sexes, the pathology was 
dominated by pituitary macro adenomas in 
47 cases, regarding the hormonal status 
51.3% were non secreting pituitary 
adenomas, the rate of operability in our 
series was 65.2%,  the surgical indication 
has been given mainly by the hormonal 
status and involvement of the optic 
apparatus which in our series was 51%, the 
invasion of the cavernous sinus has been 
appreciated according the Knosp criteria (7) 
and grade 3 and 4 was present in 44% of the 
cases. The most used surgical approach was 
the pterional approach in 83% and the 
remaining 17% by the transsphenoidal 
approach. The most frequent surgical 
corridor was represented by the 
prechiasmatic route in 54%, gross total 
resection was achieved in 51%. The most 
frequent postoperative complication 
encountered in our series was represented 
from systemic complication the meningitis 
13%, as for endocrine complication it was 
represented by transitory diabetes insipidus 
in 23.4% and SIADH in 4.2% (2 cases). The 
follow up at 3 months showed no cases of 
early recurrence, from the group of patient 
with STR 6 were sent to radiotherapy. The 
follow up at 1 year has comprised 3 deaths, 
3 cases of hydrocephalus treated with 
ventriculoperitoneal derivation, 19 cases 
were with no imagistic or clinical 
symptoms of tumour and 22 presented with 
imagistic evidence of stable residual tumour 
with no clinical symptoms. 
Conclusions: The main surgical 
indication in pituitary adenomas is 
represented by the secreting hormonal 
status of the patient (excepting prolactin 
secreting tumours) and the impairment of 
the vision. The most frequent surgical 
approach was represented by the 
transcranial (pterional) approach due to the 
large dimensions and invasiveness of the 
tumours presented in our series but also the 
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surgical team preference (in the absence of 
intracranial endoscopy at those times).  
Keywords: pituitary adenoma, pituitary 
apoplexy, prolactinoma, sellar region. 
Introduction 
Sellar tumours have a large histological 
variability and represent approximately 10-
15% of all intracranial neoplasms, from 
them pituitary adenomas represent 95% of 
lesions. Pituitary adenomas can be classified 
according their size in micro adenomas 
(<10mm), macro adenomas (>10mm) and 
giant adenomas (>40mm) (20). According 
to their functional status pituitary adenomas 
are classified as non secreting pituitary 
adenomas (NSPA) or as secreting pituitary 
adenomas (SPA) with different subtypes 
depending on the secreted hormone 
(prolactin/growth hormone etc). At 
presentation there are three main types of 
complaints: 1. Symptoms caused by tumor 
dimension with compression to the 
adjacent structures (optic chiasm/ 
diencephalon/cavernous sinus) (24) 2. 
Symptoms produced by abnormal secretion 
of hormones insufficiency/hyper secretion 
(acromegaly/Cushing’s disease) 3. 
Incidental findings – patient explored for 
some other pathology (6, 8). A particular 
clinical presentation is represented by 
pituitary apoplexy with altered level of 
consciousness, intracranial hypertension 
signs, blindness caused by sudden 
expansion of tumor volume secondary to 
intratumoral hemorrhage/infarction and 
with clear surgical indication (18, 24). The 
actual management of those tumors varies 
from surveillance, medical treatment, 
surgery or a combined approach; however 
surgery remains the main therapeutic 
method (25). 
 
Material and method 
We have retrospectively analyzed all 
cases of pituitary adenomas which were 
addressed to the 3rd Neurosurgical 
Department at N. Oblu Hospital between 
Jan 2006 and Dec 2010, during this period 
of time eighty three patients were consulted 
and 72 cases were included in the study, we 
have excluded the patients younger than 
eighteen years old, patients with previous 
surgery for pituitary adenomas and patients 
who refused the proposed therapeutic 
method according to our protocol (figure 1 
and 2). 
All patients underwent clinical 
neurological evaluation: significant 
neurological deficits were notes (3rd nerve 
palsy, signs of hydrocephalus, altered level 
of conscious, visual impairments) and the 
time interval from beginning of symptoms 
to presentation. 
Imagistic evaluation consisted in contrast 
enhanced MRI with details upon the sellar 
region. Tumor dimension was recorded 
and also the invasion into the adjacent 
structures (3rd ventricle/sphenoid sinus) 
invasion of the cavernous sinus was 
assessed according to Knosp classification, 
routinely the surgical site was analyzed by 
CT in the first day postoperatively and then 
by contrast enhanced MRI at 3 and 12 
months. Unoperated patients were 
imagistic followed up using contrast 
enhanced MRI at 12 months. 
Endocrine evaluation consisted in 
evaluation for free cortisol, ACTH, PRL, 
GH, TSH, fT4, to assess for endocrine 
derangements, except 2 cases who 
presented with pituitary apoplexy. 
Ophthalmologic evaluation consisted in 
visual acuity determination and perimetry. 
The patients were assessed for treatment 
according to the tumor size, endocrine 
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status and visual disturbance using the 
following algorithms, treatment options in 
our series were represented by surveillance, 
medical treatment and surgery. There were 
two main surgical techniques: trans 
sphenoid or trans cranial approach, we have 
noted the surgical corridors used during 
intervention, the degree of resection by 
surgeon intra operative appreciation and on 
CT scans performed on the 1st day 
postoperatively, the postoperatively 
complications (local/systemic). 
Results 
We have included in our study a number 
of 72 patients who presented for pituitary 
adenoma pathology. The cohort was 
composed of 39 females and 33 males, with 
a mean age of 50.0 years (ranged 16-75 
years). Our series contains a number of 25 
cases of micro adenomas from which 6 
undergone surgical resection and 47 cases 
of macro adenomas, with 41 cases operated 
on. The majority of patients who 
underwent resection sought medical 
attention for symptoms related to visual 
impairment (51%). The remaining patients 
complained of severe headaches (19%), 
symptoms related to hormone production 
(16%) or cranial nerve palsy/epileptic 
seizures (7% both). 15% of our patients 
presented with pituitary apoplexy 
confirmed by the MR imaging and the intra 
operative aspects.  
 
 
Figure 1 Therapeutic approach in pituitary micro adenomas (<10mm) according to their endocrine 
functioning status. 
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Figure 2 Therapeutic approach in pituitary macro adenoma (>10mm) according to their functional endocrine 
status and their effect upon intracranial optic structures 
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operations (83%) were performed using a 
transcranial route (pterional approach), the 
rest of the operated patients (8 cases) had a 
sublabial transsphenoidal approach. The 
unoperated patients (25 cases) 34.8% 
beneficiated from conservatory treatment 
(dopaminergic agonists) in 12 cases (48%), 
imagistic surveillance in 11 patients, and 2 
patients were sent to gamma knife 
according to their preference. The mean 
time for surgical intervention was 3h30’ 
with no clear difference between the 
transcranial and transsphenoidal 
approaches. The degree of resection in our 
series was noted according to the subjective 
intraoperative appreciation and objectively 
sustained on the 1st day CT scan, as result 
we have obtained gross total resection 
(GTR) in 51% of operated cases.  
The most frequent surgical corridor 
used was represented by the pre chiasmatic 
route in 54 % and opticocarotidian route in 
24%, the transsphenoidal route was used in 
12 % of the cases while the 
translaminaterminalis and 
carotidooculomotor route were used in 6% 
and 4% respectively The surgical 
complications were divided into systemic 
complications and were represented by 
meningitis in 6 cases, as for local surgical 
complications we had 16 cases of 
hematomas in the surgical bed from them 
only 1 necessitating evacuation and 2 cases 
of CSF leak 1 spontaneous closed. 
The postoperative status was assessed 
and revealed no endocrine deficiency in 60 
% cases, transitory diabetes insipidus in 23.4 
%, 4.2% had SIADH and 6% had 
panhypopituitarism. 
The outcome of patients operated on for 
pituitary adenomas consisted in 2 per 
operative deaths (death in the first 30 days 
after surgery – 1 case of pulmonary 
embolism and another of severe water 
electrolytes imbalance), 4 cases had no 
amelioration of visual symptoms, and 1 
patient had a new neurological deficit (left 
hemiparesis); the rest of the patients had a 
good surgical outcome. 
At three months follow up we had one 
early recurrence (AP: adenocarcinoma), 22 
patients had no imagistic evidence of 
intracranial tumor, from the group of 
patients with residual tumor 6 were sent to 
radiotherapy and the rest were symptom 
free and kept under surveillance. 
The follow up at 1 year comprised 
contrast enhanced MRI evaluation and 
clinical neurological examination, 19 
patients had no imagistic or clinical 
evidence of residual tumor, in 21 patients 
the imagistic evaluation detected residual 
tumour but without clinical symptoms, this 
category of patients being kept under 
imagistic and endocrine surveillance, we 
had three recurrences and the treatment 
was represented by surgery. The mortality 
in our group at 1 year was 6.3% (3 patients), 
as late complications we had 3 cases of 
hydrocephalus 2 in the group of GTR an 1 
in the group of STG – all treated with 
ventriculoperitoneal derivation. 
 
TABLE 1 
Early complications in 47 patients 
operated for pituitary adenoma 
Type of 
Complication 
No. of 
patients % 
Treatment 
Meningitis 6 (13) Antibiotics 
Blood collection 16 (34) Evacuation (1)
CSF leak  2 (4.2) Surgical 
closure (1) 
Transitory  DI 11 (23.4) Desmopresin 
SIADH 2 (4.2) Water 
restriction 
Panhypopituitarism 3 (6.3) Hormone 
replacement 
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A                                                      B                                                    C 
Figure 3 T1 contrast enhanced IRM coronal A and axial 
B sections showing a hypo intense, non enhancing lesion, in the left pituitary gland 
C CT scan in the 1st day after transsphenoidal surgery in a 60 y o female with acromegaly and GH 47.8μg/L 
 
 
A                                                      B                                                    C 
 
D                                                      E                                                    F 
Figure 4 MRI examination T1 with contrast enhancement axial (A)/sagital (C) and T2 axial showing a sellar and 
suprasellar mass hyperintense in T1 and axial T2 (B) with inhomogeneous contrast enhancement suggestive for 
pituitary apoplexy, (D) CT scan on 1st day postoperatively (transcranian) in the same 50y old F patient in treatment 
with Dostinex® for a known prolactinoma who presented with visual loss and impaired consciousness. (E) and (F) T1 
contrast enhanced MRI at 3 months showing a residual tumor in the left cavernous sinus. 
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Discussion  
Our experience has brought us to the 
conclusion that the treatment of pituitary 
adenomas should be multidisciplinary, 
namely, endocrinological, surgical and 
radiotherapeutical. The order in which 
treatment is applied is dependent on the 
tumour size, hormonal status of the patient 
and the clinical condition of the patient.  
The goals of surgery are to remove the 
tumor, relieve the mass effect, improve 
visual abnormalities, reduce hormone 
hypersecretion to normal levels, and 
preserve normal pituitary function (16), 
surgery is the first-line treatment in 
pituitary adenomas with compression upon 
optic structures and visual impairment and 
in all actively secreting adenomas except 
prolactinomas (16). Either transcranial or 
transsphenoidal approaches can be adopted 
in the surgical treatment of  pituitary 
adenomas, in our cohort the most used 
surgical approach was transcranial 
(pterional) due to the preference of the 
operative team and due to the complexity of 
the cases (CS invasion Knosp 3 and 4 in 
40%) in our series cavernous sinus invasion 
was directly correlated with STR, safe 
complete resection of tumor lateral to the 
carotid artery remaining nearly impossible 
with no regards to the surgical corridor 
used (3, 22, 23), also the suprasellar 
extension of the tumor (58.3% in our 
series), recommend considering the 
transcranial approach as the natural choice 
unless the tumour suspected to be 
hemorrhagic (1, 4). In reality, surgery is 
very effective in relieving the mass effect; 
however, most patients harboring a large 
lesion will require additional treatment to 
produce hormonal remission and prevent 
regrowth of residual tumor, and many will 
require hormone replacement therapy to 
reestablish a normal hormonal balance (3, 
8, 27).   
 Radiation treatment (conventional, 
stereotactic, or proton- beam) of the 
pituitary is most commonly used as an 
adjunctive treatment after incomplete 
tumor resection (19). Radiotherapy reduces 
the risk of residual tumor enlargement and 
offers the chance of permanent control of 
hormone hyper secretion, in our series 6 
patients of 23 with incomplete resection 
were treated using stereotactic radiation 
therapy. In our cohort the rate of gross total 
resection was achieved in only 51% of the 
cases that is lower than literature data (1, 
23).   
Surgical indication is also guided by the 
functional status of the pituitary adenoma, 
all secreting pituitary adenomas have 
surgical indication except prolactinomas, in 
which the first line of treatment is oral 
administration of a dopamine agonist, such 
as cabergoline, bromocriptine, or pergolide 
(8, 16) (more than 90% of patients respond 
to this treatment with reduction in the 
serum PRL level and with tumor 
shrinkage). 
It is known that approximately 60% of 
patients with a GH-producing tumor are 
found to harbor a macro adenoma that is 
often invasive, making its complete removal 
unlikely - this is the reason we prefer to 
operate GH secreting pituitary adenomas at 
moment of diagnosis, without previously 
use of somatostatin analog (attitude that is 
still a controversy in the literature) (8, 16). 
On the other hand there is a clear surgical 
indication for ACTH secreting adenomas, 
in which there is no effective medical 
therapy to reduce ACTH production or 
decrease tumor size, surgical removal of the 
lesion being the first choice of therapy. If 
the surgery is not successful, pituitary 
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irradiation should be considered and 
medical therapy with ketoconazole. As for 
non functional adenomas, there is no 
effective medical treatment, surgery being 
the primary therapeutic option according to 
their volume and clinical symptoms (15). 
Another clear surgical indication, given 
by the clinical status of the patient, is 
represented by pituitary apoplexy – surgical 
emergency (comprises visual deficits, 
ophthalmoplegy, hypopituitarism, altered 
levels of consciousness) the apoplexy rate in 
our group was 15%, greater than data in the 
literature (10%) (1, 12), the apoplexy was 
encountered only in macro adenomas in 
our series from which 13 were non 
functional macro adenomas and 2 were GH 
secreting adenomas. In the literature there 
are several theories concerning the 
precipitating factors in apoplexy, Biousse et 
al. divide this factors in: 1) factors 
associated with reduced blood flow, 2) 
acute increase in blood flow, 3) stimulation 
of the pituitary gland, and 4) the 
anticoagulated state (2, 12) however in our 
series we did not managed to identify 
precipitating factors such as (surgical 
intervention, postpartum status, 
radiotherapy, head injury) (2, 12, 18). 
Regarding the postoperative 
complications, the most frequent was 
represented by meningitis 13%, the rate of 
CSF leaks was encountered in only 2 cases 
both after transsphenoid surgery from 
which one was closed spontaneously. One 
particularity of our operated pituitary 
adenoma is represented by the packaging of 
the pituitary fosa after tumor removal with 
pure alcohol for 3 minutes in order to 
destroy the remnant of any neoplasic cells; 
also all of our patients beneficiated from 
glucocorticoid therapy (prednisone acetate) 
administrated pre operatively 25mg/day in a 
fractionated fashion and continued in the 
post operatively with progressively 
decreasing doses. This attitude is due to the 
fact that patients undergoing pituitary 
adenoma surgery may be prone to 
hypocortisolic states due to pre-existing or 
newly developed hypothalamic-pituitary-
adrenal axis impairment, in order to avoid 
potentially life threatening hypocortisolic 
states which may appear in patients with 
HPA impairment, adequate corticoid 
replacement therapy is considered 
mandatory (5, 10). Of course in the 
literature there is no consensus regarding 
these attitude because some authors 
administer peri-operative corticoid 
replacement medication regardless of the 
pre-operative HPA integrity while others 
limit peri-operative corticoid substitution to 
patients with impaired HPA. Also, the 
reported dosages of corticoids administered 
per operatively differ (5, 10, 17). 
Postoperatively endocrine status showed 
transitory diabetes insipidus in 23.4% from 
which 4.2% developed the second phase of 
diabetes insipidus, SIADH, it is very 
important to make the difference between 
these two conditions with similar clinic 
manifestations because the treatment is 
completely different. None of our patients 
developed the third phase of diabetes 
insipidus, the permanent phase. There are 
several theories regarding the post operative 
fluid balance disorders such as: 
mobilization of previously third space soft-
tissue fluid especially in patients harboring 
GH secreting tumors, baseline elevations in 
the levels of renin, angiotensin, atrial 
natriuretic peptide, and arginine vasopressin 
in patients with acromegaly have been 
implicated in this phenomenon, and their 
reduction after surgery likely contributes to 
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the diuresis experienced by patients via a 
reduction in sodium retention (26). 
There is well known the triphasic 
response of the diabetes insipidus,1) the 
first phase of diabetes insipidus is initiated 
by a partial or complete pituitary stalk 
section, which severs the connections 
between the cell bodies of AVP-secreting 
neurons in the hypothalamus and their 
nerve terminals in the posterior pituitary 
gland, which prevents AVP secretion this 
phase is usually treated with single doses of 
parenteral desmopressin in order to 
decrease polyuria and minimize the 
occurrence of hyponatremia due to 
overtreatment, 2) the second phase is 
dominated by the  inappropriate 
antidiuresis, which is caused by 
uncontrolled release of AVP from either 
degenerating posterior pituitary tissue, or 
from the remaining magnocellular neurons 
whose axons have been severed, 3) the third 
phase develops if >80-90% of the AVP-
secreting neuronal cell bodies in the 
hypothalamus have degenerated and which 
results in permanent diabetes insipidus ; 
these patients being best managed with 
long-term administration of intranasal or 
oral desmopressin (9) 
 In our protocol we follow up clinical 
and imagistic the operated patients at 3 
months, in order to avoid IRM artifacts 
after per operative administration of 
corticosteroids (used to avoid pituitary 
insufficiency).  
Results at 3 months showed one early 
recurrence (with tumor regrowth and 
significantly clinical symptoms - the patient 
was re operated and the histology showed 
pituitary adenocarcinoma ΚI 67 18% (21)), 
22 patients had no imagistic evidence of 
intracranial tumor, from the group of 
patients with residual tumor 6 were sent to 
radiotherapy and the rest were symptom 
free and kept under surveillance. Gamma 
Knife surgery is a commonly used 
adjunctive treatment for patients with a 
residual or recurrent adenoma, or in 
patients with persistent hormone 
hypersecretion. Decreasing the adenoma 
volume by resection and temporarily 
withholding pituitary suppressive 
medications seem to be prudent approaches 
prior to radiosurgery (13, 14).  We have sent 
to radiotherapy only the cases with 
significant mass lesions and especially non 
functional pituitary adenomas (3) in which 
is known the lack of medical treatment. 
The endocrine status at three months was 
represented by the presence of 
panhypopituitarism in 6% (treated with 
hormonal substitution) of the cases with no 
other endocrine deficits. The visual 
symptoms had no improvement in 4 
patients (16.6% of patients who were 
operated on and presented with visual 
impairment) but with no cases of worsened 
vision. In a recent paper Schramm and 
coworkers published the results of visual 
outcome in patients with pituitary 
adenomas and preoperative chiasma 
syndrome, according to them the syndrome 
completely regressed in 42.9%, improved in 
38.3%, remained unchanged in 11.2% and 
worsened in 7.4% of the patients 
postoperatively (11) 
It is also believed that visual acuity 
improvement is significant during the first 
two postoperative weeks, with no further 
significant improvement after this period 
while visual field defects significantly 
improve during the first two weeks 
postoperatively and continue to improve for 
the first three months but no later than 
that; this affirmation given the idea that 
maximum visual improvement after 
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pituitary surgery is at three months 
postoperatively (11). 
Results after 1 year follow up showed 19 
patients with no imagistic or clinical 
evidence of residual tumor, in 20 patients 
the imagistic evaluation detected minimal 
residual tumour but without clinical 
symptoms, this category of patients being 
kept under imagistic and endocrine 
surveillance, we had three recurrences and 
the treatment was represented by surgery, 
the mortality in our group at 1 year was 
6.3% (3 patients - 2 per operatively deaths  
first month following surgery and 1 after 6 
months with no relation to the surgery). 
Late complications in our series were 
represented by the appearance of 
hydrocephalus, we had three cases of 
hydrocephalus at 1 year follow up who 
presented with Hakim-Adams syndrome 
and without any imagistic sign of 
obstruction, all of them being treated with 
ventriculoperitoneal derivation 1 case 
presented with hydrocephalus at the time of 
diagnostic and the condition did not 
remitted after surgery but the other two 
cases developed the hydrocephalus post 
operatively. 
Conclusions 
In our series the main surgical approach 
was the transcranial (pterional) route due to 
the complexity of the cases (large tumors 
with extension into the suprasellar region 
and into the cavernous sinus) and the 
preference and experience of the operating 
team. The packaging of the sella with pure 
alcohol after protecting the optic structures 
seems to be a safe procedure with no 
contribution to visual deterioration, the rate 
of pituitary apoplexy is greater than the rate 
cited in the literature with no predisposing 
factors identified that should represent a 
signal of alarm because pituitary apoplexy 
represent a life threatening condition that 
must be recognized and needs adequate 
urgent treatment. 
Pituitary adenoma remains a pathology 
with lot of controversies and in which 
further randomized studies are need in 
order to clarify them although usually the 
operation is not the end of the problem, 
given the potential need for hormone 
treatment before and after surgery, 
additional treatment such as pituitary 
radiation therapy, and the risk for 
recurrence. Patients with pituitary lesions 
require lifelong follow up by all physicians 
(endocrinologist, neurosurgeon, and 
radiation oncologist) involved in their care. 
A coordinated, multidisciplinary approach 
to the care of these patients should result in 
successful care and optimal outcomes. 
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